Drugs / GEN1053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05435339 | Oct 2022 → May 2024 | cancer | Genmab | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435339 ↗ |
| Action | Activate | “GEN1053 is an antibody designed to (re)activate and increase antitumor immunity.” NCT05435339 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068607 ↗ |
| Route | Intravenous | “GEN1053 will be administered as an intravenous (IV) infusion every 3rd week.” NCT05435339 ↗ |